Cellular Biomedicine's AlloJoin therapy approved in China

|About: Cellular Biomedicine Group... (CBMG)|By:, SA News Editor

Cellular Biomedicine Group's (NASDAQ:CBMG) AlloJoin therapy for Knee Osteoarthritis (KOA) has been approved as the first stem cell KOA drug application in China for a Phase II clinical trial, following a 60-day priority review period.

Subscribe for full text news in your inbox